0 Items
Select Page

Corynebacterium diphtheriae

Diphtheria is a serious bacterial infection of the respiratory tract and remains a healthcare risk in parts of the world where vaccine coverage is low.

Diphtheria can cause serious inflammation of the throat. Corynebacterium diphtheriae bacteria release a toxin that leads to the formation of a thick greyish-white membrane coating the back of the throat and in the most severe cases, blocks the airways. Infection can be fatal.

At The Native Antigen Company, we offer both purified and activity tested diphtheria toxin and antibodies specific to the toxin, for IVD assay development and vaccine R&D.

Corynebacterium diphtheriae Background

The gram-positive bacterium, Corynebacterium diphtheriae was first identified in 1888 as the causative agent for the infectious disease known as diphtheria. The bacterium is spread from person-to-person through contaminated aerosols, distributed by coughing or sneezing, and through contact with surfaces contaminated with infectious secretions.

Diphtheria primarily affects the throat and upper respiratory tract, but its toxin is known to affect other organs. The symptoms of the disease are a sore throat, malaise, low-grade fever and swollen neck glands. The toxin can also cause a membrane of dead cells to form over the throat and tonsils, resulting in breathing difficulties, and in some cases death from asphyxiation. In severe cases, the toxin may cause neurological complications or heart failure. Patients with diphtheria are currently treated with antibiotics to kill the bacteria, and antitoxin to neutralise the effects of the diphtheria toxin (CDC).

Since 1945, diphtheria vaccination programs have been successful in reducing cases of diphtheria worldwide by 99%. However, diphtheria is still a significant problem in some countries and outbreaks have been reported in the former Soviet Union, India, Myanmar, Malaysia and the Philippines, possibly due to ineffective immunisation programs and poor vaccine quality. In addition, waning immunity to diphtheria toxin may occur in individuals who have been immunised in childhood but have not been exposed to diphtheria in later life. Various global studies report that diphtheria seronegativity increases with age, suggesting that booster vaccinations may be necessary in adults (WHO, 2017).

References

  1. Freeman VJ, Morse IU. (1952). Further observations on the change to virulence of bacteriophage-infected a virulent strains of Corynebacterium diphtheria. J Bacteriol. Mar;63(3):407-14.
  2. Center for Disease Control and Prevention: Diphtheria
  3. World health Organization: Diphtheria vaccine. Review of evidence on vaccine effectiveness and immunogenicity to assess the duration of protection ≥10 years after the last booster dose. April 2017
  4. Center for Disease Control and Prevention: Diphtheria, prevention

Corynebacterium diphtheriae Antigens

Diphtheria toxin (DT) is a 62 kDa protein belonging to the family of ADP-ribosylating bacterial toxins. It is secreted by toxic strains of Corynebacterium diphtheriae, carrying a lysogenic bacteriophage that encodes the toxin gene (Freeman, 1951).

Our purified DT is used in immunoassay manufacturing, but is also widely used in cell biology applications for depletion of DT-receptor expressing cells in transgenic mouse models. Every batch of our DT is activity tested in cellular depletion assays.

Corynebacterium diphtheriae Antibodies

Corynebacterium diphtheriae antibodies supplied by The Native Antigen Company recognise diphtheria toxin and are suitable for immunoassay research and development.

We offer two antibodies, one specific to the A chain of the diphtheria toxin. These antibodies can be used as a pair in immunoassay design.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Flavivirus NS1: A Short Introduction

In the first of a two-part series, we describe the structure of Flavivirus Non-Structural Protein 1 (NS1) and the role that it plays in viral pathogenesis. Flavivirus proteins Flaviviruses are single-stranded, enveloped RNA viruses, belonging to the Flaviviridae...

Paper Synopsis: ELISA formats and antibody quenching to reduce ZIKV cross-reactivity

While the 2015/16 Zika epidemic no longer makes the headlines, there remains a crucial need to accurately and reliably diagnose Zika virus (ZIKV) infection to identify and manage further outbreaks. However, high levels of cross-reactivity among cocirculating...

Viral Lysates for Diagnostic Research

We've recently expanded our range of native viral cell lysates to complement our highly pure recombinant antigens. Here, we explain how our lysates are made and their uses in infectious disease R&D.What are viral lysates? Put simply, viral lysates are extracts of...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 9 =

Live Customer Feedback